- Home
- ADCT vs DFP Comparison
ADCT vs DFP Comparison
Compare ADCT & DFP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ADCT | DFP |
|---|---|---|
| Founded | 2011 | 2013 |
| Country | US | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 484.4M | 429.0M |
| IPO Year | 2019 | N/A |
Fundamental Metrics
Financial Performance| Metric | ADCT | DFP |
|---|---|---|
| Price | $4.22 | $21.95 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $7.60 | N/A |
| AVG Volume (30 Days) | ★ 668.5K | 51.6K |
| Earning Date | 03-27-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.73% |
| EPS Growth | ★ 44.90 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $70,837,000.00 | N/A |
| Revenue This Year | $12.48 | N/A |
| Revenue Next Year | $5.12 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.84 | N/A |
| 52 Week Low | $1.05 | $18.20 |
| 52 Week High | $4.80 | $22.11 |
Technical Indicators
Market Signals| Indicator | ADCT | DFP |
|---|---|---|
| Relative Strength Index (RSI) | 62.46 | 73.63 |
| Support Level | $3.85 | $21.40 |
| Resistance Level | $4.23 | $22.05 |
| Average True Range (ATR) | 0.27 | 0.16 |
| MACD | 0.04 | 0.03 |
| Stochastic Oscillator | 95.07 | 87.30 |
Price Performance
Historical ComparisonAbout ADCT ADC Therapeutics SA
ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. In addition, it also has various other product candidates in its pipeline, such as ADCT-602, Claudin-6, PSMA, NaPi2b, and ASCT2. Geographically, the company generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).
About DFP Flaherty & Crumrine Dynamic Preferred and Income Fund Inc.
Flaherty & Crumrine Dynamic Preferred and Income Fund Inc is a diversified, closed-end management investment company. Its investment objective is to seek total return, with an emphasis on high current income.